Tuesday September 20
|
|
7:30 - 8:50
|
Registration – Nunavut - 4th floor
Breakfast – Confederation III
|
|
8:50 - 9:00
|
Welcome from CellCAN – Regenerative Medicine and Cell Therapy Network
Denis Claude Roy, CEO, CellCAN
Confederation I & II
|
|
9:00 - 9:20
|
**Special announcement**
|
|
Theme 1: Pushing beyond the limits of CGT manufacturing
The need for greater biomanufacturing capacity has been on the steady rise in Canada, even prior to the onset of the COVID-19 pandemic. Increased domestic biomanufacturing capacity as a pandemic response element has driven the need beyond recent forecasts and forced manufacturers to deploy novel strategies to increase production within existing facilities. Theme 1 will explore novel initiatives, innovative technologies deployed by academia, industry and government to reduce bottlenecks and ramp up domestic biomanufacturing.
Moderator: Renaud Manuguerra-Gagné
Chair: David Courtman, Scientist, Director of Biotherapeutics, Ottawa Hospital Research Institute
Confederation I & II
|
|
9:20 - 10:20
|
Building Momentum for now and the Future: Canadian Biomanufacturing Strategy and Investment, Rodrigo Arancibia, Innovation Science and Economic Development, Government of Canada
Biomanufacturing and enabling capabilities at the NRC: vaccines and beyond, Kelley Parato, Director, Cell and Gene Therapy Challenge Program, Human Health Therapeutics Research Centre, National Research Council of Canada
Confederation I & II
|
|
10:20 - 10:40
|
Health break and exhibitors visit
|
|
10:40 - 12:00
|
Challenges and answers to Cell Therapy Manufacturing - Issues and solutions to launching clinical trials - Cancer Immunotherapy production for clinical trials and the pathway to commercialization - Louisa Petropoulos, CEO, C3i
Biomanufacturing - Gatekeeper of success in cell & gene therapy, Michael May, CEO, CCRM
Panel discussion: Pushing beyond the limits of CGT
- Kasondra White, Director of Strategy, Life Sciences and Biomanufacturing Branch, Innovation Science and Economic Development, Government Canada
- Kelley Parato, Director, Human Health Therapeutics, NRC
- Louisa Petropoulos, CEO, C3i
- Michael May, CEO, CCRM
Confederation I & II
|
|
12:00 -13:30
|
Lunch, networking and exhibitors visit
Confederation I & II
|
|
Theme 2: Solving the talent development crisis for CGT manufacturing
Biomanufacturing has been identified as the major bottleneck for the advancement of the gene therapy sector as the exponential growth of the field has placed an increasing demand for additional biotherapeutics manufacturing capacity under cGMP. The problem is exacerbated by the dearth of qualified talent required to fill the specific job roles for biomanufacturing; this phenomenon is encountered in every jurisdiction around the globe. A unique opportunity exists to leverage the strengths and synergies between well recognized training and funding organizations to contribute substantially to growing the cell and gene therapy sector, and fill the dearth in available talent of HQP trained and qualified for workflow under aseptic conditions This session will detail initiatives underway to attack the talent development crisis and ensure job creation for the production of advanced therapies.
Moderator: Renaud Manuguerra-Gagné
Chair: Gayle Piat, Operations Manager, Alberta Cell Therapy Manufacturing
Confederation I & II
|
|
13:30 - 15:00
|
Canadian Advanced Therapies Training Institute (CATTI): solving the talent crisis through efficient, advanced training solutions - Craig Hasilo, Chief Scientific Officer, CATTI
Mitacs: Internships for biomanufacturing and biosciences - Fernanda Mendonça, Business Development Specialist, Mitacs
adMare Academy Executive Institute - Developing Canada's life science leaders in a COVID world and beyond - Kristy Lonegan, Senior Director, adMare Academy Sponsored by: 
Panel discussion on solving the talent development crisis
- Craig Hasilo, Chief Scientific Officer, CATTI
- Paul-Xavier Etter, Director of Training, CASTL
- Jennifer Quizi, Director of Manufacturing, OHRI Vector BMC, Director Biotherapeutics Manufacturing Operations, Program Coordinator, CanPrime
- Fernanda Mendonça, Business Development Specialist, Mitacs
Confederation I & II
|
|
15:00 - 15:20
|
Health break and exhibitors visit
|
|
15:20 - 15:40
|
Impact of ALS and treatment options - A caregiver and patient advocacy vision
Patient advocate: Jan Mattingly, ALS Action Canada, mother of ALS patient Wayne Mattingly
Confederation I & II
|
|
15:40 - 16:10
|
The next frontier of health: Canada’s growing regenerative medicine sector, Cate Murray, President & CEO, Stem Cell Network
Sponsored by: 
Confederation I & II
|
|
Theme 3 - Sector Investment: Doing business in Canada
The rapid pace of innovation within the CGT sector has sparked tremendous growth potential and investment opportunities. Reducing manufacturing costs, expanding manufacturing capacity, increasing the domestic supply chain, addressing the bottlenecks in the field, including the required skilled workforce, are all critical elements for continued sector growth. This session focuses on doing business in the Canadian CGT ecosystem, including space allocation for biomanufacturing under GMP, creation of new GMP facilities, government programs, and securing investment from venture capital and other sources.
Moderator: Renaud Manuguerra-Gagné
Chair: Cynthia Lavoie, President & Chief Investment Officer, CCRM Enterprise
Confederation I & II
|
|
16:10 - 16:50
|
Panel discussion
- Ella Korets-Smith, Chief Business Officer, Virica
- Louisa Petropoulos, CEO, C3i Center
- Jonathan Yeh, Partner, Saisei Ventures
Confederation I & II
|
|
16:50 - 17:00
|
Wrap-up of day 1
Armand Keating, Chair, CellCAN Strategic Advisory Committee; Senior Scientist, Krembil Research Institute and Clinician Scientist, Princess Margaret Cancer Centre
Confederation I & II
|
|
18:00 - 21:00
|
CATTI Launch Networking Event - Sponsored by
Westin Twenty-Two
|